Characterization of B cells in muscle-specific kinase antibody myasthenia gravis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 2, 2015, Pages e77-

  Guptill, Jeffrey T ^a   Yi, John S ^a   Sanders, Donald B ^a   Guidon, Amanda C ^a   Juel, Vern C ^a   Massey, Janice M ^a   Howard, James F ^b   Scuderi, Flavia ^c   Bartoccioni, Emanuela ^c   Evoli, Amelia ^c   Weinhold, Kent J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; COMPLEMENT; CYCLOSPORIN; MUSCLE SPECIFIC TYROSINE KINASE; MYCOPHENOLATE MOFETIL; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; MONOTHERAPY; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PHENOTYPE; PLASMABLAST; PRE B LYMPHOCYTE; PRIORITY JOURNAL; YOUNG ADULT;

EID: 85014290751     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000077     Document Type: Article

References (42)

1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyro-sine kinase MuSK in patients with myasthenia gravis with out acetylcholine receptor antibodies. Nat Med 2001;7: 365-368.
2. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myas-thenia gravis. Brain 2003;126:2304-2311.
3. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
4. Guptill JT, Sanders DB. Update on muscle-specific tyro-sine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010;23:530-535.
5. Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and-negative myasthenia gravis. Neurology 2005;64:536-538.
6. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010;41:370-374.
7. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44:36-40.
8. Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66:1772-1774.
9. Bartoccioni E, Scuderi F, Augugliaro A, et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009;72:195-197.
10. Farrugia ME, Bonifati DM, Clover L, Cossins J, Beeson D, Vincent A. Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 2007;185: 136-144.
11. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscu-lar junction. Ann Neurol 2008;63:782-789.
12. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myas-thenia. Neurology 2012;78:189-193.
13. Yi JS, Guidon A, Sparks S, et al. Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun 2013;52:130-138.
14. Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(1) CD251 T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005;105:735-741.
15. Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(1)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol 2012;145:209-223.
16. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501.
17. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008;118:3420-3430.
18. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012;14:R32.
19. Sun F, Ladha SS, Yang L, et al. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 2014;49:487-494.
20. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
21. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-444.
22. Iwata Y, Matsushita T, Horikawa M, et al. Characteriza tion of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117: 530-541.
23. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012;12:191-200.
24. Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 2013;48: 992-993.
25. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-3056.
26. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-453.
27. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
28. Kim JY, Yang Y, Moon JS, et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008;199:151-154.
29. Ragheb S, Lisak R, Lewis R, Van Stavern G, Gonzales F, Simon K. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008;65:1358-1362.
30. Scuderi F, Alboini PE, Bartoccioni E, Evoli A. BAFF serum levels in myasthenia gravis: effects of therapy. J Neurol 2011;258:2284-2285.
31. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-3930.
32. A randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, tolerability, and pharmaco-dynamics of belimumab in subjects with generalized myasthenia gravis (MG). ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT01480596? term5belimumab&rank535. Accessed May 6, 2014.
33. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221-241.
34. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-950.
35. Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic auto-immunity. J Immunol 2010;184:4801-4809.
36. Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memory B cells: syner-gistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998;91:173-180.
37. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-297.
38. Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009;158: 155-163.
39. Heine G, Drozdenko G, Grun JR, Chang HD, Radbruch A, Worm M. Autocrine IL-10 promotes human B-cell differentiation into IgM-or IgG-secreting plasma-blasts. Eur J Immunol 2014;44:1615-1621.
40. Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006;67: 505-507.
41. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307:769-775.
42. Sanders DB, Burns TM, Cutter GR, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 2014;49: 483-486.